Dianthus Therapeutics vs Immunome
Immunome reported revenue of $7 million in fiscal 2025, 3.5 times Dianthus Therapeutics' $2 million in fiscal 2025. Dianthus Therapeutics' revenue fell 67.3% in its latest year, and Immunome's fell 23.2%. Dianthus Therapeutics had an operating margin of -8739.3%, against -3228.8% at Immunome. Free cash flow was −$129 million at Dianthus Therapeutics and −$201 million at Immunome.
Side by side
| Dianthus Therapeutics | Immunome | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $2M | $7M |
| Revenue growth | −67.3% | −23.2% |
| Revenue growth a year, last 5 years | — | — |
| Gross margin | — | — |
| Operating margin | −8,739.3% | −3,228.8% |
| Net margin | −7,973.3% | −3,060.0% |
| Free cash flow | −$129M | −$201M |
| Free cash flow margin | −6,349.4% | −2,890.1% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 15.9% | 49.0% |
| Last close | $91.81 | $18.77 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $79.2 million | bought $2.3 million, sold $27.5 million |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Dianthus TherapeuticsImmunome
Operating margin
Percent of revenue
Dianthus TherapeuticsImmunome
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Dianthus TherapeuticsImmunome
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Dianthus Therapeutics and Immunome pages.